The Duke Human Vaccine Institute (DHVI) has established a place of national and international leadership in the fight against major infectious diseases. DHVI plays an integral leadership role in the Global HIV/AIDS Vaccine Enterprise and is a pioneer in emerging infections and biodefense research. By focusing on the scientific “bottlenecks” for the development of HIV, TB, and other vaccines, DHVI investigators continue to make significant contributions to overcome global health challenges on behalf of society. More

Press Releases

Human Immunodeficiency Virus

Recent Publications

Spectrum of HIV antibodies in vaccine and disease.

Tomaras GD, Montefiori DC. Curr Opin HIV AIDS. 2014 May; 9(3): 207-9.

Autoreactivity in HIV-1 broadly neutralizing antibodies: implications for their function and induction by vaccination.

Verkoczy L, Diaz M. Curr Opin HIV AIDS. 2014 May; 9(3): 224-34.

Modulation of HIV-1 immunity by adjuvants.
Moody MA. Curr Opin HIV AIDS. 2014 May; 9(3): 242-9.

Video Presentations

Broadly neutralizing HIV-1 antibody identified in a lupus patient
March 11, 2014
Dr. Barton Haynes, DHVI and Duke CHAVI-ID Director, discusses recent findings from a study led by DHVI investigators in which a broadly neutralizing antibody was identified in a lupus patient who was chronically infected with HIV.